Shattuck Labs, Inc. (STTK) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 1.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $1.00M | (m) | (m) |
| 2026-03-31 | (m) | $1.00M | (m) | (m) |
| 2025-12-31 | (m) | $1.00M | (m) | (m) |
| 2025-09-30 | (m) | $1.00M | (m) | (m) |
| 2025-06-30 | (m) | $3.00M | (m) | (m) |
| 2025-03-31 | (m) | $4.61M | (m) | (m) |
| 2024-12-31 | (m) | $5.72M | (m) | (m) |
| 2024-09-30 | (m) | $6.43M | (m) | (m) |
| 2024-06-30 | (m) | $4.12M | (m) | (m) |
| 2024-03-31 | (m) | $2.71M | (m) | (m) |
| 2023-12-31 | (m) | $1.66M | (m) | (m) |
| 2023-09-30 | (m) | $1.33M | (m) | (m) |
| 2023-06-30 | (m) | $859.00K | (m) | (m) |
| 2023-03-31 | (m) | $709.00K | (m) | (m) |
| 2022-12-31 | (m) | $652.00K | (m) | (m) |
| 2022-09-30 | (m) | $30.34M | (m) | (m) |
| 2022-06-30 | (m) | $32.03M | (m) | (m) |
| 2022-03-31 | (m) | $27.75M | (m) | (m) |
| 2021-12-31 | (m) | $30.02M | (m) | (m) |
| 2021-09-30 | (m) | $1.28M | (m) | (m) |
| 2021-06-30 | (m) | $1.82M | (m) | (m) |
| 2021-03-31 | (m) | $9.23M | (m) | (m) |
| 2020-12-31 | (m) | $9.93M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $9.89M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |